Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.41 |
| ▸ | ATR | Q13535 | 7/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177420 | 0.95 | ATR (0.43) | NAMPTATRFEN1ATMPRKDC | |
| SCHEMBL16420718 | 0.89 | NAMPT (0.45) | NAMPTATRCYP2C9 | |
| SCHEMBL16069993 | 0.88 | ATR (0.54) | ATRFEN1ATMPRKDC | |
| SCHEMBL16069984 | 0.84 | ATR (0.57) | ATRATMPRKDC | |
| SCHEMBL18177405 | 0.84 | ATR (0.47) | NAMPTATRATMPRKDC | |
| SCHEMBL16420716 | 0.84 | ATR (0.40) | ATRATMPRKDC | |
| SCHEMBL16420725 | 0.83 | PRKDC (0.39) | NAMPTATRFEN1ATMPRKDC | |
| SCHEMBL16420526 | 0.83 | ATR (0.50) | ATRATMPRKDC | |
| SCHEMBL18177383 | 0.81 | ATR (0.46) | NAMPTATRFEN1ATMPRKDC | |
| SCHEMBL3050739 | 0.81 | ATR (0.47) | ATRFEN1ATMPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311809-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | NAMPT 1940/4885ATR 1/4885FEN1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.